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Abstract
Background: Estrogen receptors alpha (ERa) and beta (ERb) are transcription factors (TFs) that mediate estrogen
signaling and define the hormone-responsive phenotype of breast cancer (BC). The two receptors can be found
co-expressed and play specific, often opposite, roles, with ERb being able to modulate the effects of ERa on gene
transcription and cell proliferation. ERb is frequently lost in BC, where its presence generally correlates with a better
prognosis of the disease. The identification of the genomic targets of ERb in hormone-responsive BC cells is thus a
critical step to elucidate the roles of this receptor in estrogen signaling and tumor cell biology.
Results: Expression of full-length ERb in hormone-responsive, ERa-positive MCF-7 cells resulted in a marked reduction
in cell proliferation in response to estrogen and marked effects on the cell transcriptome. By ChIP-Seq we identified
9702 ERb and 6024 ERa binding sites in estrogen-stimulated cells, comprising sites occupied by either ERb,E R a or both
ER subtypes. A search for TF binding matrices revealed that the majority of the binding sites identified comprise one or
more Estrogen Response Element and the remaining show binding matrixes for other TFs known to mediate ER
interaction with chromatin by tethering, including AP2, E2F and SP1. Of 921 genes differentially regulated by estrogen
in ERb+ vs ERb- cells, 424 showed one or more ERb site within 10 kb. These putative primary ERb target genes control
cell proliferation, death, differentiation, motility and adhesion, signal transduction and transcription, key cellular
processes that might explain the biological and clinical phenotype of tumors expressing this ER subtype. ERb binding in
close proximity of several miRNA genes and in the mitochondrial genome, suggests the possible involvement of this
receptor in small non-coding RNA biogenesis and mitochondrial genome functions.
Conclusions: Results indicate that the vast majority of the genomic targets of ERb can bind also ERa, suggesting
that the overall action of ERb on the genome of hormone-responsive BC cells depends mainly on the relative
concentration of both ERs in the cell.
Background
Estrogens are key regulators of cell growth and differen-
tiation in the mammary gland [1,2], where they are
involved in the pathogenesis and clinical outcome of
breast cancer (BC) [3]. These steroid hormones exert
their effects in normal and transformed mammary
epithelial cells by binding to specific receptors, ERa and
ERb, that mediate estrogen signaling by functioning as
ligand-dependent transcription factors. Ligand-activated
ERs drive gene cascades comprising primary genes,
whose transcription is directly controlled by the hormone
through physical interaction of ERs with regulatory sites
in the genome (genomic pathway) and/or with signal
transduction effectors (non genomic pathway), as well as
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functions encoded by the primary responders [1,4].
ERs are able to bind DNA at specific sites in the gen-
ome and thereby control gene activity by recruiting tran-
scriptional mediators and co-regulators, as well as a host
of other nuclear proteins with different roles in ER-
mediated control of gene activity [5,6]. The two ERs
show 55% identity in their estrogen-binding domains
(LBDs) and approximately 97% similarity in the DNA-
binding domains (DBDs) [7]. Reflecting the high degree
of similarity in their DBDs, both receptors interact with
the same conserved estrogen response element (ERE) (5’-
GGTCAnnnTGACC-3’) as either homodimers or alpha/
beta heterodimers [8,9]. ERb,h o w e v e r ,h o l d sl o wt r a n s -
acting capability on ERE-containing estrogen target genes
and alpha/beta heterodimers are less efficient than ERa
homodimers in promoting target genes activity [10]. The
different behaviour of ERa/ERb heterodimers respect
to ERa homodimers on transcriptional regulation of
ERE-containing genes might be explained by different
co-factor recruitment, as ERb could prevent efficient
co-activator binding to the ERa moiety of the heterodi-
mer, conversely inducing recruitment of co-repressors
and/or driving assembly of co-regulatory complexes
other than those involving ERa only. [8,11,12].
Although the two receptors are quite similar in
sequence and structure, in BC ERb has considerably dif-
ferent biological effects than ERa [1,13,14]. Further-
more, the two ERs show a remarkably different
expression pattern in BCs, with higher ERa and lower
ERb levels observed in malignant cells compared to nor-
mal mammary epithelial or benign tumor cells [15,16].
Furthermore, while ERa induces a mitogenic response
to estrogen, when expressed alone the b subtype is not
only unable to induce the same mitogenic response, but
it reduces basal, hormone-independent cell proliferation
[17-18 and R. Tarallo et al., unpublished]. Finally, ERb
was shown to change dramatically ERa-positive BC cell
behaviour in vivo, as its expression in the cell prevents
tumorigenicity in mouse xenograft models by reducing
tumor growth and angiogenesis [19,20].
Gene expression studies performed in BC cell lines
expressing endogenous ERa and recombinant ERb
[21-23] revealed multiple signaling pathways involving
the a and/or b receptor subtypes [1]. The two ERs
appear thus to share many target genes, although each
of them may affect specific downstream targets. For this
reason, inhibition of hormone-responsive BC cell growth
by ERb might be due to direct interference with ERa
activity on growth-promoting pathways as well as to the
activity of ERb-specific target genes [24].
Recently, next-generation sequencing technologies
combining chromatin immunoprecipitation (ChIP)
either with genomic DNA hybridization to microarrays
(ChIP-on-chip) or massively parallel sequencing (ChIP-
Seq, ChIP-PET), opened new venues for our under-
standing of physical and functional associations between
transcription factors and chromatin in vivo. These analy-
tical strategies led to genome-wide mapping of ERa-
binding regions in intact chromatin of cultured cell lines
[25-28], revealing important new information relative to
ERa interaction with the genome. Carroll et al. [25], for
example, using ChIP-on-chip demonstrated that the
Forkhead factor FoxA1 plays an important role as pio-
neering factor for ERa binding to chromatin in BC cells,
while Cicatiello et al. [26] identified novel gene regula-
tion cascades mediating estrogen actions in hormone-
responsive BC cells. In contrast, although several studies
focused on ERb interaction with the genome [29-32], a
thorough characterization of this important aspect of
ERb biology in BC cells, essential to clarify the mechan-
isms mediating its control of estrogen-dependent gene
pathways and the hormone-responsive phenotype, is still
missing. For this reason, we performed a comprehensive
analysis of ERb and ERa target sites in the genome of
MCF-7 cells engineered to express both receptors to
comparable levels, by integrating global mapping of in
vivo ER binding to the genome by ChIP-Seq with com-
parative gene expression profiling in ERb+/ERa+ vs
ERb-/ERa+ cells during early stimulation with 17-beta-
estradiol (E2), followed by in silico analyses of the ERb
binding regions and responsive genes identified.
Results and Discussion
Establishment and characterization of ERb-expressing
MCF-7 cells
Stabilized human BC cell lines expressing endogenous
ERa and ERb at comparable levels are not available. For
this reason, we first generated and characterized cell
lines derived from ERa-positive MCF-7 cells expressing
full-length human ERb (ERb1) at levels similar to those
of endogenous ERa. This strategy was adopted to pre-
vent artefacts due to ERb over-expression in the cell
and to mimic what observed in primary breast tumors,
where very high expression of this receptor has never
been observed. As suitable antibodies for efficient
immunoprecipitation of chromatin-bound ERb are not
available, the expressed proteins were tagged on either
their C- (Ct-ERb)o rN - t e r m i n u s( N t - E R b)w i t ht h e
TAP epitope. This approach allows to track tagged ERs
in different cell compartments and to efficiently immu-
noprecipitate and purify them in vitro by Tandem Affi-
nity Purification, to identify their molecular partners
[5,33], and ex vivo in chromatin immunoprecipitation
assays (see below). Preliminary tests were performed to
verify whether the presence of the TAP moiety could
influence intracellular redistribution of ERb in response to
17b-estradiol (E2) and its ability either to trans-activate an
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Page 2 of 16estrogen-responsive reporter gene or to interfere with
ERa activity on reporter gene transcription and BC cell
proliferation. To this end, ER expression and nuclear
translocation in response to E2 was determined in wt
MCF-7, Ct-ERb and Nt-ERb cells by subcellular fractio-
nation followed by SDS-PAGE and immunoblotting
(Figure 1A). In absence of hormone a larger fraction of
both ERs was found in the cytosol in all cases. Follow-
ing estrogen stimulation, both receptors migrated to the
nucleus, a crucial event to trigger target gene transcrip-
tion via the genomic pathway of the estrogen signaling
cascade. An antibody against a-tubulin was used as
control, and the absence of this protein in the nuclear
fractions indicates that they were indeed free from cyto-
solic contaminants. The ERb-expressing clones selected
for this study showed a ERb/ERa ratio <2, as verified by
immunoblotting analysis of the proteins in whole cell
extracts and quantitative rtPCR of the corresponding
RNAs [5, and data not shown]. To control that the pre-
sence of the TAP tag did not interfere with ERb activity,
ER-negative SKBR-3 BC cells were transiently trans-
fected with expression vectors encoding wt ERb,C t -
ERb,N t - E R b,E R a (HEG0) or ‘empty’ vector (pSG5), as
controls, and ERE-tk-luc [34], a reporter gene where
luciferase expression is driven by an estrogen-respon-
sive minimal promoter. Exposure of transiently trans-
fected cells to E2 induced reporter gene activation in
t h ep r e s e n c eo fE R a,E R b,C t - E R b or Nt-ERb,w i t ht h e
activity of both tagged ERb proteins slightly (15-20%)
lower than that of wt ERb (Figure 1B, left). We then
tested whether the two recombinant forms of ERb were
able to interfere with target gene activation by the
endogenous ERa resident in MCF-7 cells. To this end,
wt,C t - E R b+a n dN t - E R b+ cells were transfected with
ERE-tk-luc and the response of the reporter gene to E2
was determined. As shown in Figure 1B (right), ERb-
expressing cells showed in all cases a marked (50-60%)
reduction in reporter gene response to the hormone,
when compared to wt MCF-7 cells, indicating that both
tagged ERbs are able to interfere with the activity of
endogenous ERa. Results show that cell lines stably
expressing Ct-ERb and Nt-ERb display a marked reduc-
tion in proliferative response to the hormone, when
compared to wt MCF-7 cells (Figure 1C), in agreement
with the known effects of ERb in ERa-positive cells
[23,35-37]. Furthermore, comparative RNA expression
profiling in exponentially growing Ct-ERb and Nt-ERb
vs wt MCF-7 cells revealed extensive overlapping effects
of the two tagged ERb proteins on the activity of estro-
gen target genes [O. Paris et al., manuscript in prepara-
tion and data not shown]. Taken together, these
Figure 1 Functional characterization of ERb-expressing MCF-7
cells. (A) Nuclear translocation of ERa and ERb shown by western
blot analysis on cytosolic (c) and nuclear (n) protein extracts,
prepared from wt MCF-7, Nt-ERb and Ct-ERb cells after treatment
with either 17b-estradiol (10
-8M, +E2) or vehicle alone (-E2) for 45
minutes. The amount of a-tubulin was also analyzed to verify the
absence of cytosolic contaminants in the nuclear fractions. (B) The
transcriptional activity of ERa, Nt-ERb and Ct-ERb was measured by
transient transfection in SKBR3 cells (left) and the ability of tagged
ERb to interfere with ERa activity was assessed by comparing
estrogen effects in wt, in Nt-ERb and Ct-ERb MCF-7 cells (right); in
all cases transiently transfected ERE-tk-luc was used as reporter
gene. (C) Proliferation of wt MCF-7, Nt-ERb and Ct-ERb cells was
measured by stimulating hormone-starved cells with 10
-8M E2,
followed by cell counting with a colorimetric assay at the indicated
times.
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cell lines generated for this study show a well defined
phenotype, with respect to the known activities of this
ER subtype in BC cells, and are thus suitable to investi-
gate the genomic bases of ERb actions in this cell type.
As we could not exclude that the presence of the TAP
tag at either the N- or C- term of ERb may specifically
influence its activity on cellular targets or pathways dif-
ferent from those investigated above, all experiments
reported in this study were performed in both Ct-ERb
and Nt-ERb cells and the data were combined for analy-
sis, with the aim to focus on the most significant and
reproducible actions of ERb independently from posi-
tion of the tag in the receptor moiety.
Effects of ERb on the estrogen-responsive MCF-7 cell
transcriptome
Expression of ERb is known to cause significant changes
in the genomic response to estrogen in target cells. To
identify the genes whose estr o g e nr e g u l a t i o ni nh o r -
mone-responsive BC cells is perturbed by ERb,w ep e r -
formed gene expression profiling with microarrays in
estrogen-starved, quiescent wt and TAP-ERb+( C t - E R b
and Nt-ERb) MCF-7 cells following stimulation with
10
-8M E2. Total RNA was extracted from the three cell
lines either before or after 2, 4 or 8 hrs stimulation, fluor-
escently labelled and analyzed on whole-genome micro-
arrays. Samples extracted from the two ERb-expressing
cell lines were pooled before analysis, to reduce the
impact of clone-specific differences and to focus on the
most significant effects of ERb, independent from tag
position in the protein. Results obtained in these samples
were then compared with those obtained under the same
conditions in wt MCF-7 cells. This analysis yielded 921
transcripts differentially regulated by the hormone in
ERb+ vs ERb- cells (Figure 2), including 234 mRNA
whose regulation was detected only in wt MCF-7 cells,
516 regulated only in ERb+ cells (see Venn diagram in
Figure 2), 154 showing a similar pattern of response in
both cell types (up- or down-regulated in all cases,
although at different levels) and 17 showing opposite
responses to the hormone in ERb+ vs ERb- cells (14 tran-
scripts repressed in wt cells but activated in ERb+ cells
and 3 showing an opposite behaviour). The full list of
these differentially regulated transcripts is reported, with
relevant information, in Additional Table S1. Taken
together, these results indicate that the presence of ERb
greatly influences the response of the MCF-7 cell genome
to estrogen, by interfering with ERa-mediated hormonal
regulation of 405 genes (Figure 2, left and central panels)
and promoting de novo regulation of 516 genes (Figure 2,
right panel). It should be noted that these analyses were
performed with data obtained after 8 hrs of hormonal sti-
mulation, a timing that allowed us to focus on early
response genes, positioned upstream in the composite
transcriptional cascade set in motion by the hormone in
this cell type and more likely to include primary genomic
t a r g e t so fE R s[ 2 6 ] .I ti st h u sp o s s i b l et h a tt h i sa n a l y s i s
missed ERb-responsive genes showing significant changes
in expression only at later times after hormonal stimula-
tion. However, analysis of the global effects of ERb on
gene expression in these same cells, performed as
described above in cultures exponentially growing under
continuous hormonal stimulus, suggests that the number
of regulated transcripts identified here is rather close to
the total number of genes targeted by this ER subtype in
MCF-7 cells [O. Paris et al., manuscript in preparation].
Global mapping of ERa and ERb binding to MCF-7 cell
genome
The widespread effects of ERb on MCF-7 cell transcrip-
tome are likely to result from multiple effects of this
Figure 2 Gene expression differences in absence or presence
of ERb. Top: Heatmap summarizing the effects of ERb expression of
the estrogen responsive transcriptome of MCF-7 cells, showing
changes in expression (log2 of the fold-change) of 921 transcripts
after cell exposure to 10
-8M E2 for the indicated times. Transcripts
are grouped as follows: regulated only in wt MCF-7 cells (1), in both
cell lines (2) and only in TAP-ERb cells (3). Bottom: Venn diagram
showing the numbers of differentially regulated by E2 in wt MCF-7
only (1), both cell lines (2) or ERb expressing cells only (3).
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mary response genes via genomic or non genomic
mechanisms, and indirect gene regulation events
mediated by the products of primary genes. The primary
ERb target genes are most likely to comprise also master
regulators of complex cellular responses to the receptor,
mediating its effects on the biological and clinical phe-
notype of BC cells. To identify such primary genomic
targets and investigate the mechanisms that allow their
regulation by ERb, a global analysis of in vivo binding of
this receptor to the genome was carried out in TAP-
ERb cells by chromatin immunoprecipitation coupled to
massively parallel sequencing (ChIP-Seq) [38], that
allows detailed mapping of in vivo TF binding to the
genome. In parallel, we studied ERa binding to the gen-
ome under the same conditions, to allow comparative
analyses between the two ER subtypes. Replicate chro-
matin samples were prepared from both Ct-ERb and
Nt-ERb cells before and after stimulation for 45 minutes
with 10
-8M E2 and DNA-bound proteins were immuno-
precipitated either with antibodies against the N- and
C-terminus of ERa, or with IgGs binding with high affi-
nity the TAP moiety of tagged ERb (see Methods). Preli-
minary testing on several known ERb binding sites,
including the promoter-near region of pS2/TFF1 gene
[26], confirmed that the method selected to immunopre-
cipitate chromatin-bound Ct-ERb and Nt-ERb was effi-
cient and specific (data not shown). The resulting DNAs
were used to generate ChIP-Seq libraries for ERa and
ERb, respectively, that were then sequenced with the
Illumina Genome Analyzer. The sequence tags obtained
were then aligned to the human genome sequence and
peaks enriched in the libraries generated after E2-treat-
ment were identified using MACS (Model-based Analy-
sis of ChIP-Seq) [39]. This led to the identification of
9702 binding sites for ERb and 6024 sites for ERa,o f
which 4506 were shared by both receptors (Figure 3A),
with an average False Discovery Rate (FDR) of 3%. The
full list of these binding sites is available, with relevant
information, in Additional Files 1 and 2. Interestingly,
about half (4862) ERb binding sites identified map
within transcription units, mainly (3942 sites) in intronic
regions. This distribution is maintained also in 424 ERb-
regulated transcription units (see below), where 966 ERb
binding sites located in the gene or within 10 kbps from
it are distributed as follows: 154 in promoter regions, 51
in exons, 471 within one or more introns and the
remaining either upstream of promoters (156) or down-
stream of the gene (134). In both cases the ERb binding
sites within genes did not show any preference with
respect to exon or intron position nor for know intra-
genic regulatory elements (splice sites, polyadenylation
sites, etc). It should be mentioned that the number of
ERb binding sites identified is significantly higher that
those mapped in MCF-7 cells by ChIP-on-chips [30,31],
possibly for technical differences due to ERb expression
levels in the different MCF-7 cell-derived clones used, in
immunoprecipitation efficiency and/or in DNA analysis.
Since only Zhao et al. [31] performed an unbiased
search for ERb binding with whole-genome chips, we
could confront our results only with those reported in
that study. This showed that 86% of high confidence
ERb sites described in that study appear also in our
dataset. The binding sites identified here were then sub-
jected to sequence analysis, searching first for the pre-
sence of EREs (Estrogen Receptor Elements), the
characteristic ER binding signature (Figure 3B). This
analysis revealed that in all three cases (i.e. ERb,E R a
and ERb+ERa) a high percentage of sites displayed one
or more imperfectly palindromic ERE (ERE+), with a
slightly higher positivity in ERa sites (58.89 vs 53.51%).
As ERs have been shown to bind both in vitro and in
vivo to PuGGTCA hemi-palindromes (hEREs), we
Figure 3 Sequence analysis of ERa,E R b and ERa+ERb binding
sites. (A) Venn diagram showing a summary of ERa and ERb
binding sites identified in TAP-ERb cells by ChIP-Seq. (B)
Classification of ERa and b binding sites based on the presence of a
perfectly or imperfectly palindromic Estrogen Response Element
(ERE, green), an ERE hemipalindrome (hERE, blue) or no ERE (none,
red). (C) ERE motif matrices identified in each of the three ER
binding regions indicated (left), classification of the binding sites
belonging to each region according to the presence of ERE (center)
and grid summarizing the results of TFBS matrix enrichment
(overrepresentation) analyses performed on the binding sites groups
indicated (right). Z-Score cut-off was 3.0 and only TFBSs showing an
over-representation score ≥4.0 in at least one of the ERE- (none)
binding site groups. Light grey cells indicate a Z-Score <3.0 while
dark grey cells indicate absence of the matrix.
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perfect matches to this sequence. Results showed that
almost half of them indeed contained one or more
hEREs. The percentages of sites not carrying a known
ER-binding element (ERE- and hERE-) were similar for
both receptors (ERa: 22.34%, ERb: 28.38%). We observed
that ERa and ERb binding sites were often found in close
proximity to each other, a confounding factor when
attempting to discern and analyze separately ER subtype-
specific sites and target genes. This could be due to the
limits of the ChIP-Seq technology or of the algorithm
used for peak selection. To overcome this problem, and
allow the identification of potential ER subtype-specific
sites, we used a cartographic approach to group nearby
binding sites that might be the result, at least in part, of
shortfalls of the mapping methods applied. Each binding
peak was thus elongated in both directions by 1000 bp
and the overlapping ones obtained were merged into
8536 ERb and 5371 ERa ‘extended’ binding regions.
These regions were intersected to define ERa only, ERb
only or ERa+ERb binding regions. In this way we could
identify 1271 ERa-only and 4541 ERb-only binding sites,
comprised in these regions, none of which showed
nearby binding of the other receptor. These were named:
ER subtype ‘prevalent’ sites. The binding peak sequences
included in each of the three regions obtained (ERa only,
ERb only or ERa+ERb) were then re-analyzed for the
presence of ERE or hERE elements. In this way we could
observe that sites within the ERa+ERb regions showed
now a much higher percentage of ERE+ sequences
(62.90%), respect to those present in the ERa-only or
ERb-only regions (45.63% and 44.62%, respectively, Fig-
ure 3C). Since all three types of sites showed almost iden-
tical proportions of hERE+, this result suggests that
perfectly or imperfectly palindromic EREs are preferential
binding sequences for ERa-ERb heterodimers, while ERa
and ERb homodimers appear to be more flexible in DNA
recognition. ERE+ sequences were then analyzed in more
detail with MEME [40], to investigate if the three classes
of sites identified showed any difference in the relative
base composition of their respective ERE signatures. For
each list of sequences, the most significant position-
specific probability matrix generated by MEME was
compared to the matrices present in the JASPAR tran-
scription factor binding profile database [41], using the
STAMP tool-kit for DNA motif comparison [42]. As
s h o w ni nF i g u r e3 C( l e f tp a n e ls), this analysis revealed
that the ERE matrices derived from the three types of
binding regions identified (ERa selective, ERb selective
and ERa+ERb) are identical and, as a consequence, that
ERb does not appear to display ERE variant selectivity.
We then examined the ERE- sequences to search for
enriched binding motifs for other transcription factors
that might play a role in ER binding to chromatin in the
absence of canonical EREs. ERs are known to be able to
bind chromatin indirectly, by physically interacting with
DNA-bound TFs (tethering), including SP1 [43,44] or
the AP1complex [31,45,46], for gene trans-regulation.
TFBS enrichment respect to the whole genome was cal-
culated thus in ERE- sites with using the RegionMiner
tool [47] and only statistically significant (Z-score ≥3.0)
and highly enriched (over-representation ≥4-fold)
matrices were further considered. The results are sum-
marized in the right panel of Figure 3C, showing for
comparison the over-representation values scored in
hERE+ and ERE+ sites by the same matrices selected in
the ERE- sites. These numerical values, together with
relevant information, are reported in Additional Table
S2 [Additional file 3]. The enriched matrices found in
the ERE- set of ERb prevalent sites include V$SP1.01, V
$SP1.02, V$SP1.03, V$SP2.01 and V$GC.01, all belong-
ing to the GC-Box family targeted by SP1 and GCFC1
(GC-rich sequence DNA-binding) factors, V$CTCF.01
and V$CTCF.02, binding site matrices for the CCCTC-
binding factor CTCF, that is a known transcriptional
repressor of c-myc [48], V$NRF1.01, binding NRF1
(nuclear respiratory factor 1), a transcription factor that
regulates the expression of nuclear-encoded mitochon-
drial genes [49], V$ZF5.01, for the POZ domain zinc
finger protein ZF5, and V$ZNF9.01, recognized by the
zinc finger proteins ZNF148, 202, 219 and 281. The
majority of these TFs bind GC- and C-rich sequences
that are structurally related to each other, suggesting the
possibility that a significant portion of the sequence
elements listed above might indeed be recognized by
one or a limited number of TFs. On the other hand, the
V$GAGA.01 matrix was specifically enriched only in the
ERa prevalent ERE- binding sites. This sequence binds a
transcription factor known to influence chromatin struc-
ture in Drosophila [50] and to bind throughout the gen-
ome [51], but nothing is known about physical or
functional interactions of this factor with ERs or other
nuclear receptors. The results of this analysis point to
T F st h a tc o u l da c ta sp a r t n e r so fE R b for binding to
chromatin in the absence of canonical EREs. Interest-
ingly, the majority of these same matrices were found
enriched also in the ERb binding sites comprising
hEREs or EREs (Figure 3C), suggesting that one or more
such DNA matrices might cooperate with ERb for either
DNA binding or gene trans-regulation. We performed a
direct search for conserved motifs in the ERE- binding
sites of ERb with MEME [40], and the most significant
position-specific probability matrices were compared to
those present in the JASPAR TF binding profile data-
base [41]. The results failed to provide any conclusive
information, as each of several sequence motifs obtained
with this analysis was found only in a small fraction of
the binding sites analyzed.
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To identify the genes directly controlled by ERb binding
to the genome, and analyze the interplay between the
two ERs in gene regulation, we combined the ChIP-Seq
data with those relative to estrogen responsive genes dif-
ferentially regulated by E2 in ERb+ vs ERb- MCF-7 cells
under the same experimental conditions (Figure 2).
Three sets of ER binding regions (defined as described
in Methods) were used for this analysis: ERb (8872, Set
1) and ERa (5558, Set 2) binding regions identified in
TAP-ERb cells, and all ERa binding regions identified
so far in wt MCF-7 (17888, Set 3). The regions from Set
1( E R b in ERb+ cells) were intersected with those from
Set 2 (ERa in ERb+ cells), to define which of them was
binding both receptor subtypes (’heterodimer ERa+ERb’:
4186), only ERb (’homodimer ERb’: 4686) or only ERa
(’homodimer ERa’: 1372) in TAP-ERb cells. The ‘homo-
dimer ERb’ and the ‘heterodimer ERa+ERb’ groups were
further filtered against Set 3 binding regions (ERa sites
detected in ERb- cells), to identify the genomic sites
recognized by ERb, with or without ERa,b u tn e v e rb y
ERa alone. This allowed us to classify the sites com-
prised in these regions as follows: Class 1, including
2126 sites occupied by ERa in wt MCF-7 cells and by
ERb in TAP-ERb cells (ERb vs ERa competition); Class
2, showing 4340 sites where ERa can bind in wt MCF-7
cells and both receptors are detected in TAP-ERb cells
(ERb+ERa); Class 3, with 2707 sites binding only ERb
and never, under any condition, ERa (ERb specific);
Class 4, comprising 529 sites where both receptors are
found in TAP-ERb cells but none in wt MCF-7 cells
(ERb+ERa specific); Class 5, including 617 sites where
ERa binds only in TAP-ERb but never in wt cells (ERa
displacement); Class 6, composed of 773 sites that bind
only ERa both in wt and TAP-ERb cells (ERa specific).
When combined with the results of the sequence ana-
lyses described above, this classification reveals that
ERb-specific cis-acting regulatory elements are unlikely
to exist in the genome, as all evidence point to the fact
that the two ER subtypes can recognize identical
sequence features.
To identify among the genes differentially regulated by
estrogen in ERb+ vs ERb- cells those representing direct
targets for transcriptional regulation by DNA-bound
ERb in our cell model, we extracted from the list in
Additional Table S1 [Additional file 3] the genes bearing
one or more ERb binding sites inside or within 10 kb of
the TU, and termed them ‘primary’,t oi n d i c a t et h a t
they are most likely to respond directly to the signal
conveyed by the E2-activated receptor [26]. Of these
424 genes - listed in Additional Table S3 [Additional file
3], whose kinetics of response to E2 in wt and TAP-ERb
cells is shown in Figure 4, 52 show one ERb site of
Class 1 (ERb vs ERa competition), 90 a site of Class 2
(ERb+ERa), 71 a site of Class 3 (ERb specific) and only
9 a Class 4 site (ERb+ERa specific), while 202 showed
multiple ERb sites belonging to different classes and
were thus classified accordingly (grey in Figure 4). In
the right panels of Figure 4 are reported examples for
each of the primary gene classes described above, show-
ing the location of the receptor binding sites respect to
the promoter and structural gene. It is worth mention-
ing that when the gene expression data from wt MCF-7
cells stimulated with E2 for 8hrs (Figure 2) were com-
bined with information concerning ERa binding regions
identified in wt MCF-7 cells under comparable condi-
tions (Set 3 described above), 228 putative primary ERa
target genes were identified -listed in Additional Table
S4 [Additional file 3], 71% of which (163 genes) showed
ERb binding in hormone-stimulated ERb+c e l l s .T h i s
result supports the view that the two ER subtypes tend
to interact with the same targets in BC cells genome.
A functional analysis of the primary ERb target genes
identified here with Ontologizer [52] showed that most
primary ERb responsive genes are involved in key cellular
processes, including control of cell proliferation, survival
and differentiation status as well as cell motility, migra-
tion and adhesion, and can all greatly influence BC cell
phenotype and response to estrogen - listed in Additional
Table S5 [Additional file 4]. When GO analysis was per-
formed on the ERa target gene set from wt MCF-7 cells
(228 genes), results showed that the genes controlled
directly by this ER subtype appear to be involved in the
same cellular processes described above for ERb -com-
pare results reported in Additional Tables S5 and S6
[Additional files 4 and 5], providing a further indication
of the significant overlapping between gene pathways tar-
geted by ERb and ERa in BC cells. Focusing on the genes
differentially regulated by E2 in ERb- vs ERb+ cells
known for their involvement in cell proliferation, we
observed that many of them encode for transcription fac-
tors and other key proteins controlling large gene net-
works of cell division cycle and cell survival and, in
general, cell proliferation and differentiation pathways.
These include, in particular, CDK-6 (cyclin-dependent
kinase 6), CEBPA (CCAAT/enhancer binding protein,
alpha), DAB2 (Disabled homolog 2, mitogen-responsive
phosphoprotein), HES-1 (Hairy and enhancer of split
homologue 1), IGFBP-4 (Insulin-like growth factor bind-
ing protein 4), IRS-1 and -2 (Insulin receptor substrates 1
and 2), JAK-2 (Janus kinase 2), JunB, MITF (Micro-
phthalmia-associated transcription factor), MYC, SLIT-2
(Slit homolog 2, Drosophila), SMARCA-2 (SWI/SNF
related, matrix associated, actin dependent regulator of
chromatin, subfamily a, member 2), SOX-9 (Sex deter-
mining region Y-box 9), TGFB-2 (Transforming growth
factor beta 2), TGFBI/LCD-1 (transforming growth fac-
tor, beta-induced, 68 kDa), TGM-2 (Transglutaminase 2),
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Page 7 of 16Figure 4 Putative ERb primary targets. Left: Heatmap summarizing the effects of estrogen stimulation on 424 mRNAs encoded by genes
showing one (left) or more (right)E R b binding sites within 10 kb of the TU (primary response genes) transcriptome of MCF-7 cells, as changes in
expression (log2 of the fold-change) after cell exposure to 10
-8M E2 for the indicated times. Transcripts are grouped as follows: regulated only in
wt MCF-7 cells (1), in both cell lines (2) and only in TAP-ERb cells (3). Vertical bars to the right of each heatmap indicate the class of ERb binding
site present, as indicated in the legend. When a regulated gene showed multiple ERb binding sites belonging to different classes it was included
in a separate group, classified as ‘combination of ERb sites’ (grey bar).Right: Genome Browser view of genomic loci representative of the different
ERa and ERb binding site categories identified. ChIP-Seq ERa and ChIP-Seq ERb indicate sites identified in this study, ChIP-Seq ERa1, ChIP-Seq
ERa2 and ChIP-on-chip indicates sites identified in MCF-7 cells by Cicatiello et al. [26], Fullwood et al. [27], and Hurtado et al. [28], respectively.
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Page 8 of 16TNS-3 (Tensin 3) and WISP-2 (WNT1 inducible signaling
pathway protein 2). Interestingly, the role of all these genes
in tumor cell proliferation and differentiation is known and
an involvement in hormone-mediated BC cell responses to
ERa has been reported for most of them, suggesting that
discovery of an ERb direct effect on transcription of these
genes provides a new molecular framework to elucidate
the anti-proliferative and differentiative effects of this
receptor subtype in hormone-responsive cells.
Among the RNAs encoded in the genome, micro-
RNAs (miRNAs) have emerged as master regulators of
gene expression for their ability to influence mRNA
concentration and activity by post-transcriptional
mechanisms. Recent results highlighted the role of
miRNA in BC cells response to estrogen [26,53-58] and,
in addition, several lines of evidence indicate extensive
miRNA deregulation in BC, including differential
expression of miRNAs in normal vs transformed mam-
mary epithelial cells [59-61]. For these reasons, we
focused our attention on the TUs encoding pre-miR-
NAs, to test the possibility that ERb binding sites might
be located in close proximity of these genes. Results
show that 52 miRNA-encoding loci (isolated or in geno-
mic clusters) show one or more ERb site within 10 kb
from the pre-miR sequence of the host gene - listed in
Additional Table S7 [Additional file 6]. Distribution of
these sites among the ER binding Classes described
above was comparable to what observed for primary
genes. Interestingly, in several cases ERb binds both
up- and down-stream of the pre-miR locus, further sug-
gesting that receptor docking might exert multiple regu-
latory actions on miRNA biogenesis.
We tested the hypothesis that the observed distribu-
tion of sites near the pre-miRNA loci occurred at ran-
dom by applying a bootstrap approach. To this end, we
repeatedly sampled 1000 times the same number of sites
of the real ERb binding set, with the same length distri-
bution, a similar distribution among chromosomes but
randomly selected coordinates. We then counted the
number of pre-miRNA loci and the number of randomly
generated sites found within 10 kb of each other and
compared their distributions with that of the experimen-
tally detected ones. The number of randomly generated
s i t e sw i t h i n1 0k bo fap r e - m i R N An e v e rr e a c h e dt h e
value detected experimentally, while the number of
miRNA loci scoring an artificial site in close proximity
was equal or above what measured only in 7.6% of the
cases. These results can be explained also by the obser-
vation that in several cases ERb binds both up- and
down-stream of the pre-miR locus, a result that support
a functional significance of this observation. In fact, the
ratio between the number of ERb binding sites and the
number of pre-miRNA loci within 10 kb of each other
is 1.5, while this varied between 0.5 and 1 for the
randomly generated sets (data not shown). We thus
conclude that although some of the ERb sites detected
in or near pre-miRNA loci may be the result of a ran-
dom, non functional event, these is likely to represent
rare events, as random distribution never reaches the
enrichment level observed experimentally. Indeed, preli-
minary miRNA profiling analyses carried out in wt
MCF-7 and TAP-ERb cells indicate that mature miRNA
expression undergo extensive deregulation in the pre-
sence of ERb [O. Paris et al., manuscript in preparation
and data not shown], suggesting that at least some of
the sites identified here might indeed be involved in
ERb-mediated regulation of miRNA biosynthesis in BC
cells.
ERb binding to the mitochondrial genome
Mitochondrial DNA (mtDNA) is usually overlooked in
whole-genome ChIP-seq analyses, since identification of
enriched peaks is more difficult here due to a much
higher noise, consequence of the high and variable num-
ber of mtDNA copies in the cell. ERb has been shown
to localize in the mitochondria in different cell types
[62] including human BC cells [63,64], and a role for
estrogen in mitochondrial function, with implications on
cell growth, has been established [65,66]. We thus ana-
lyzed the sequence reads that aligned on the mtDNA
sequence with the same method used for whole genome
data analysis, but applying a supplementary fold-inten-
sity filter (see Methods) to deal with the higher back-
ground noise. This analysis revealed one ERb binding
site in proximity of the mtDNA D-loop, but no ERa
binding sites either in wt MCF-7 or in TAP-ERb cells
(Figure 5A). Independent ChIP analysis confirmed this
results, showing ERb binding to this same mtDNA
region upon activation by E2 or its selective agonist 2,3-
bis(4-hydroxyphenyl) propionitrile (DPN) and lack of
ERa binding (Figure 5B). Furthermore, the presence of
ERb in mitochondria of TAP-ERb cells was confirmed
biochemically, by western blotting (Figure 5C), an analy-
sis that revealed also the presence of ERa in the orga-
nelle. When we analyzed the sequence of the ERb
mitochondrial site with MatInspector, we observed the
presence of the matrix V$GATA1.06, bound by GATA1,
a factor whose activity is strongly repressed by ERa [67],
and V$HMGA.01, bound by HMGA1, a non-histone
chromosomal protein that is highly overexpressed in
cancer cells [68] and has been shown to interact with
ERa and to enhance its binding to DNA [69].
Conclusions
T h er e s u l t so ft h i ss t u d yi n d i c a t et h a tin vivo ERb can
interact with hormone-responsive BC cell chromatin
either alone or complexed with ERa, but in all cases the
two receptors share the same genomic targets. An
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Page 9 of 16observation that is in agreement with the conclusions of
previous studies based on analysis of ERa and ERb hetero-
dimerization and binding to the ERE [9,70-72]. When
both ER subtypes are expressed in the same cell, the main
action of ERb in the genome is thus achieved in combina-
tion with ERa, by either heterodimerization or competi-
tion for binding to the same target sites in chromatin.
Based on these observations, we propose that in hormone-
responsive BC the final cellular response to estrogen is
likely to depend upon the relative concentration of the
two ERs in the cell, their activation status and DNA bind-
ing kinetics and the presence of other factors influencing
their respective functions.
Methods
Plasmid preparation, cell lines, cell culture and stable
transfections
Different BC cell lines were used: MCF-7 TET Off (ER-
alpha positive; ATCC, Cat No. HTB-22) and SKBR3
(ER-alpha negative; ATCC, Cat No. HTB-30). MCF-7
TET Off cells (described here as wt or ERb-) were used
to produce stable clones expressing ERb tagged with
TAP-tag respectively at the C-term and at the N-term
(Ct-ERb and Nt-ERb)o rC - t a g g e dE R a (Ct-ERa), as
previously described [5,33]. All were grown in Dulbec-
co’s modified Eagle’s medium (DMEM), supplemented
with 10% fetal bovine serum (FBS) (both from Invitro-
gen), 100 U/ml penicillin, 100 mg/ml streptomycin, 250
ng/ml Amfotericin-B, 50 μg/ml G418 (normal growing
condition). For estrogen starvation, cells were plated at
40% confluence in steroid-free medium (phenol red-free
DMEM medium, with 5% fetal bovine serum pre-treated
with dextran-coated charcoal and antibiotics) and main-
tained for 5 days with replacement of fresh medium
before stimulation with 10
-8M1 7 b-estradiol (E2).
Preparation of cell extracts, mitochondria isolation and
immunoblotting analyses
Cells starved in 100-mm dishes were stimulated for 45
minutes, harvested in cold PBS and collected by centri-
fugation at 1000 × g. The cell pellets were then resus-
pended in three volumes of Hypotonic Buffer (HB) (20
mM HEPES pH 7.4, 5 mM Sodium Fluoride, 10 μM
Sodium Molybdate, 0.1 mM EDTA, 1 mM dithiothreitol,
1 mM protease inhibitors, 1 mM Phenylmethyl-Sulfonyl
Fluoride). Cells were then incubated on ice for 15 min
and 0.5% Nonidet P-40 followed by spinning 30 sec at
4°C at 13000 × g. Supernatants were recovered and clar-
ified at 13,000 × g for 15 min at 4°C while pellets were
resuspended in hypotonic buffer, stratified on 25%
sucrose-HB solution and centrifuged at 6000 × g for 15
min at 4°C. The resulting pellets were then resuspended
in one volume of Nuclear Lysis Buffer [73] containing
800 mM NaCl, incubated for 30 min at 4°C with gentle
shaking and centrifuged for 15 min at 4°C at 13000 × g.
The supernatant fraction was recovered.
Mitochondria were isolated from 20 × 10
6 Ct-ERb or
Ct-ERa cells (in 150 mm culture dishes) as described [74],
with minor modifications. All steps during mitochondria
isolation were performed at 4°C, cells were washed twice
in PBS, scraped, and centrifuged at 290 × g, 5 minutes.
The samples were resuspended in buffer A (250 mM
Sucrose, 50 mM Tris-HCl, 2 mM EGTA), homogenized in
Glass-Teflon Potter homogenizer and centrifuged at 600 ×
g for 3 min, then the supernatants were re-centrifuged at
the same speed. Mitochondria were pelleted by centrifuga-
tion at 10400 × g for 10 min, resuspended in buffer A
and centrifuged again at 5300 × g for 10 min, in order to
Figure 5 Mitochondrial ER-beta binding sites.( A )G e n o m e
Browser view of the ERb binding site identified in mitochondrial
genome. (B) Validation of ERb binding to mitochondrial DNA by
ChIP. Results shown are representative of duplicate analyses. E2:
10
-8M1 7 b-estradiol; PPT: 10
-8M 1,3,5-tris(4-hydroxyphenyl)-4-propyl-
1H-pyrazole (selective ERa agonist); DPN: 10
-8M 2,3-bis(4-
hydroxyphenyl) propionitrile (ERb agonist). (C) Western blot analysis
of ERb and/or ERa in purified mitochondria from Ct-ERb and Ct-ERa
[33] cells. Cyt: cytosol depleted of mitochondria, H: whole cell
homogenate; Mito: purified mitochondrial fraction. ATPase is a
mitochondrial marker and a-tubulin was included to determine the
level cytosolic contaminants in ‘Mito’ samples.
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Page 10 of 16eliminate microsomal and cytosolic contamination. The
samples were dissolved in buffer A and centrifuged at
1500 × g for 4 min and then pelleted again at 9600 × g for
10 minutes. The final pellet was resuspended in Buffer B
(50 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100,
0.1% SDS, 1% Na Deoxycholate, 1 mM PMSF, 1X Protease
Inhibitor) and incubated on ice for 20 min to extract mito-
chondrial proteins. A small portion of sample was col-
lected after homogenization and processed to obtain the
samples corresponding to homogenate and cytosol. An
equivalent protein amount was fractionated by SDS-PAGE
on Mini Protean Precast polyacrylamide gels 4-20% from
Biorad.
Homogenate, cytosol, nuclear or mitochondrial
extracts from equivalent cell number were fractionated
by SDS-PAGE. Immunoblot analysis was performed
using the following primary antibodies: Ct-ERa (HC-20;
sc-543) from Santa Cruz Biotechnology, Inc., TAP tag
(CAB1001) from Open Biosystems, a-Tubulin (T 6199)
from Sigma-Aldrich, ATPase B (ab14730) from Abcam.
Peroxidase-labelled anti-rabbit or -mouse immunoglobu-
lin antisera were used according to the manufacturer’s
instructions (Amersham Italia).
Transient Transfections and Luciferase Assay
Wild type MCF-7, Ct-ERb and Nt-ERb clones were
starved for 5 days in estrogen-free medium. Then 5 ×
10
5 cells/dish were seeded in 60 mm culture dishes and
transfected by using 25 μg/dish polyethylenimine (Poly-
sciences, Inc.) with 2.5 μg/dish DNA, including 300 ng
ERE-tk-Luc [75], 500 ng pSG-Δ2-NLS-LacZ vector [76],
co-transfected as an internal control for transfer effi-
ciency, and carrier DNA (Bluescribe M13+). At 48 hrs
after transfection, cells were treated for 24 hrs with
either vehicle (EtOH) or E2 (10
-8M).
SKBR3 cells were grown to 60-70% confluence and
transfected with Lipofectamine 2000 reagent (Invitro-
gen) and OPTI-MEM (Invitrogen) according to the
manufacturer’s instructions. The plasmids used were
pSG5-ERb, encoding full-length ERb (ERb1), pSG-
HEGO, encoding the full-length ERa and the corre-
sponding pSG5 empty vector (Stratagene), pUSE-C-
TAP-ERb and pUSE-N-TAP-ERb, encoding full-length
ERb tagged, respectively, at the C-term and at the N-
term [5], ERE-tk-Luc and pSG-Δ2-NLS-LacZ. Six hours
after transfection, the medium was changed and 24 hrs
later cells were stimulated as described above for 24 hrs.
At the end of treatment, cells were washed with cold
PBS and lysed in 100 μl lysis buffer (Promega). Lucifer-
ase activity was measured in extracts using the Lucifer-
ase Assay Reagent (Promega), according to the
manufacturer’s instructions, and values were expressed
as relative light units normalized to the b-galactosidase
activity or to the protein concentrations measured using
the Bradford technique. For each condition, average
luciferase activity was calculated from the data obtained
from three independent dishes.
Cell Cycle Analysis
Estrogen-deprivation was always controlled by cell cycle
analysis as follows. Cells (1.5 × 10
5 cells/dish) were
starved in 60 mm culture dishes, stimulated for 27 hrs
and collected in PBS containing 50 μg/ml propidium
iodide, 0.1% (v/v) sodium citrate, 0.1% (v/v) Nonidet P-
40. Cell samples were incubated in the dark for at least
15 min at room temperature, or overnight at 4°C, and
analyzed by a FACScalibur flow cytometer using the
CellQuest software package (BD Biosciences), according
to standard protocols suggested by the manufacturer
[77,78]. Data analysis was performed with Modfit soft-
ware (Verity Software, Topsham). Values were plotted
as increasing of S-phase respect to unstimulated con-
t r o l s .R e s u l t ss h o w e dw e r eo b t a i n e df r o mt w oi n d e p e n -
dent experiments.
Cell Proliferation Assay
Hormone-starved cells (3000/well) were seeded in 96-
well dishes. After 12 hrs, medium was changed to
include the indicated compounds. After appropriate sti-
mulation, cells were washed in phosphate-buffered sal-
ine (PBS) and fixed with 12.5% glutaraldehyde for 20
min at room temperature, followed by washing with dis-
tilled water, incubation with 0.05% methylene blue for
30 min, rinsing and incubation with 0.33 M HCl for 18
hrs. Absorption was measured at 620 nm.
RNA purification
Total RNA was extracted from wt MCF-7, Ct-ERb and
Nt-ERb clones, generated as described above, using the
standard RNA Extraction method with TRIzol (Invitro-
gen) method, as described previously [79,80]. Cells were
estrogen-deprived and total RNA was extracted before
or at the indicated times after stimulation with 10
-8M
17b-estradiol (+E2) or ethanol vehicle.
In each case RNA derived from two independent
experiments performed in duplicate was used. Before
use, RNA concentration in each sample was assayed
with a ND-1000 spectrophotometer (NanoDrop) and its
quality assessed with the Agilent 2100 Bioanalyzer with
Agilent RNA 6000 nanokit (Agilent Technologies).
Microarray analyses
Total RNA extracted from Ct-ERb and Nt-ERb cells
were pooled. For mRNA expression profiling, 500 ng
total RNA were reverse transcribed, as described pre-
viously [26,81] and used for synthesis of cDNA and bio-
tinylated cRNA according to the Illumina TotalPrep
RNA Amplification Kit (Ambion, Cat. n. IL1791)
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dized for 18 hrs at 55°C on Illumina HumanHT-12 v3.0
BeadChips, containing 48,804 probes (Illumina Inc.),
according to the manufacturer’sp r o t o c o la n ds u b s e -
quently scanned with the Illumina BeadArray Reader
500. Data analyses were performed with GenomeStudio
software version 2009 (Illumina Inc.), by comparing all
values obtained at each time point against the 0 hrs
values. Data was normalized w i t ht h eq u a n t i l en o r m a l i -
zation algorithm, and genes were considered as detected
if the detection p-value was lower than 0.01. Statistical
significance was calculated with the Illumina DiffScore,
a proprietary algorithm that uses the bead standard
deviation to build an error model. Only genes with a
DiffScore ≤-40 and ≥40, corresponding to a p-value of
0.0001, were considered as statistical significant.
Chromatin Immunoprecipitation
Ct-ERb and Nt-ERb cells were hormone-deprived for 4
days and chromatin was extracted in several replicates
before (-E2) and after stimulation for 45 minutes with
10
-8M1 7 b-estradiol (+E2) or, where indicated, with the
10
-8M selective ERa agonist 1,3,5-tris(4-hydroxyphenyl)-
4-propyl-1H-pyrazole (PPT) or 10
-8ME R b agonist 2,3-bis
(4-hydroxyphenyl) propionitrile (DPN), from Tocris
Cookson.
Chromatin was prepared with the Millipore/Upstate
Chromatin Immunoprecipitation (ChIP) Assay Kit
(Millipore) according to the instruction provided by the
producer, using a variation of the protocol described at
the Upstate website. For each assay, a total of 5 × 10
6
cells were fixed with 1% formaldeyde for 10 min at
room temperature, the reaction was then stopped by
adding glycine at final concentration of 0.125 M. Fixed
cells were washed twice with ice-cold PBS, harvested by
scraping, centrifuged and the cell pellets were re-sus-
pended in SDS lysis buffer. Samples were sonicated with
a Diagenode Bioruptor (Diagenode) for 12 cycles of 30
sec at high power, centrifuged at 12500 xg for 15 min-
utes and diluted 8-fold in ChIP dilution buffer. After
removing an aliquot (whole-cell extract input), the chro-
matin sample was divided in three aliquots, that were
incubated at 4°C overnight with antibodies against either
the C-term (HC-20, from Santa Cruz Biotechnology) or
N-term (anti-Estrogen Receptor 18-32, from SigmaAl-
drich) of human ERa or with IgG Sepharose 6 fast Flow
(GE Healthcare Bio-Science AB) for TAP-ERb [5]. As
control, an aliquot of the same chromatins were pro-
cessed in the same way but Abs or IgGs were omitted
form the reaction. The samples were then precipitated
by binding to protein-A Agarose/Salmon Sperm DNA
beads (Millipore), for ERa,o ra ss u c hf o rt oE R b.T h e
beads were washed sequentially with ‘low-salt immune
complex wash buffer, ‘high salt immune complex wash
buffer, ‘LiCl immune complex wash buffer’ and TE buf-
fer, before elution in Elution buffer by ON incubation at
65°C and treatment with Proteinase K. DNA was puri-
fied from immunoprecipitated (IPP) chromatin by
extraction with phenol:chloroform:isoamyl alcohol
(25:24:1) and ethanol precipitation according to standard
procedures. DNA pellets were dissolved in nuclease-free
water and kept frozen before further use.
Primers for ChIP-QPCR validation of the mitochon-
drial genome ERb binding site were the following: 5’-
GATCACAGGTCTATCACCCTATTAACC (forward)
and 5’-CAGCGTCTCGCAATGCTATC (reverse).
Samples preparation for ChIP-Seq
DNAs from Ct-ERb and Nt-ERb cells treated with E2
were pooled together to generate an ERb +E2 sample and
the same was done for DNAs from hormone-starved
cells (ERb -E2 sample). Similarly, IPP DNAs obtained
with anti-C-term and anti-N-term ERa Abs were pooled
together to generate ERa +E2 and ERa -E2 samples.
About 20 ng of ChIP DNA was purified using the MinE-
lute PCR Purification Kit (QIAGEN, Italy), with a recov-
ery of 55-70%, as assessed with the Quant-IT DNA Assay
Kit-High Sensitivity and a Qubit Fluorometer (Invitro-
gen). Preparation of IPP DNA libraries for massively par-
allel sequencing was performed from 10 ng purified DNA
according to the Illumina ChIP-Seq sample preparation
kit protocol (Illumina Inc.). Libraries were sequenced
with the Illumina Cluster Station and Genome Analyzer
II according to manufacturer’s instructions.
ChIP-Seq data analysis
The sequence tags generated by massively parallel
sequencing were aligned on the human genome (hg18)
with the software ELAND, allowing up to 2 mismatches.
Enriched regions from ERa +E2 and ERb +E2 samples
were compared with the same from ERa -E2 and ERb
-E2 samples, respectively. The enriched ChIP-Seq peaks
were identified using MACS (Model-based Analysis of
ChIP-Seq) version 1.3.7.1 [39], with standard parameters
(p-value cut-off of 1e-5, mfold of 32). For mtDNA we
further filtered out sites with tag density below 0.5 (N/l;
N = number of tags, l = length of site)
Computational searches for ERE sequences
The ERE binding motif was searched in binding sites
with the MatInspector application [82], a part of Geno-
matixSuite software (Genomatix Software GmbH, Ger-
many). The matrices ER.01, ER.02, ER.03 and ER.04
(Genomatix Matrix Library 8.2), were used with a core
similarity threshold of 0.75 and a matrix similarity thresh-
old of Optimal -0.02. The sequences bearing a match of
any of the four matrices were termed ERE+ sequences.
On the remaining sequences, the hemi-palindromic ERE
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a custom half ERE matrix PuGGTCA (hERE). The
remaining sequences were classified as ERE- and were
scanned for other TF binding s i t e sm o t i f sc o n t a i n e di n
the Genomatix Matrix Library using the standard para-
meters, as described previously [26].
TFBS over-representation analysis
ERE- sequences were analyzed to search for known TF
binding sites (TFBSs) that were enriched (over-repre-
sented) with respect to their relative frequency in the
whole human genome. This analysis was performed with
the RegionMiner application of the Genomatix software
suite [47]. The software automatically searches for all
TFBS matches present in the submitted sequence list and
calculates the over-representation value of the actual
number of matches over the expected value based on its
frequency in the reference set (genome or promoters) for
each matrix. It reports also the significance of the over-
representation ratio, expressed as Z-scores [83]. Enrich-
ment values with a Z-score <3.0 were not considered
further. A filter was applied also on the over-representa-
tion values, depending upon the range of values set for
each analysis, to highlight only the stronger associations.
Results are shown as heatmaps representing over-repre-
sentation values, generated with MeV software [84].
Classification of ERb binding sites and identification of
primary ERb responsive genes by combining ChIP-Seq
and expression profiling data
Three sets of ER binding sites were taken in consideration.
The first and second comprised, respectively, the ERb and
ERa sites mapped in TAP-ERb cells and the third (named
‘MCF-7 ERa’) included all ERa binding sites identified in
wt MCF-7 cells by ChIP-Seq [26,27] and/or by ChIP-on-
chip [28]. First of all, the ER binding sites from ChIP-Seq
analyses were elongated in both directions by 1000 bp.
Subsequently, using UCSC Table Browser [85], for each of
the first two sets the extended sites overlapping with each
other were merged in ERb or ERa binding ‘regions’,
respectively. For the third set (wt MCF-7 ERa), the
extended ChIP-Seq sites and the ChIP-on-chip sites over-
lapping with each other in the genome were all merged to
generate unique MCF-7 ERa binding ‘regions’. To identify
putative primary ERb responsive genes, the TUs corre-
sponding to RNAs differentially regulated by E2 in ERb+
vs ERb- cells that showed one or more ERb binding region
inside or within 10 kb were extracted using UCSC Table
Browser, as described previously [26].
Gene Ontology analysis
To identify Biological Process GO terms statistically
overrepresented in our regulated gene lists, we used
Ontologizer 2.0, a tool for GO term enrichment analysis
of genes derived from an experiment [52]. We identified
enriched terms in primary ERb or ERa target genes
against all genes expressed (detected) in the cell lines
under study, set as background of the analysis, with a p
value threshold of 0.01.
Microarray and ChIP-Seq data accession numbers
The microarray and ChIP-Seq data have been deposited
in the Array Express database ( HYPERLINK “http://
www.ebi.ac.uk/arrayexpress” http://www.ebi.ac.uk/
arrayexpress) with Accession Numbers E-TABM-1051
and E-MTAB-345, respectively.
Additional material
Additional File 1: Grober_ER-alpha_Binding_Sites ERa binding sites.
The UCSC genome BED formatted file lists the chromosome, start
coordinate, stop coordinate and identifier of the ERa binding sites.
Additional File 2: Grober_ER-beta_Binding_Sites ERb binding sites.
The UCSC genome BED formatted lists the chromosome, start
coordinate, stop coordinate and identifier of the ERb binding sites.
Additional File 3: Sheet 1: Additional Table S1 Differentially
Regulated Genes. Overview of the 921 genes differentially regulated by
E2 in ERb+ vs ERb- cells, containing the following additional information:
gene set membership, symbol, Entrez ID, gene name and expression
values (fold-change). Sheet 2: Additional Table S2 TFBS enrichment matrix.
The worksheet shows the over-representation values for the TF binding
matrices from ERE- binding sites. Sheet 3: Additional Table S3 Primary ERb
target genes, showing ERb binding sites within 10 kb of the TU.
Overview of the 424 putative ERb primary gene targets containing the
following additional information: gene set membership, category of ERb
binding sites, Symbol, Entrez ID, Gene Name, TU Coordinates, ERa
Binding Sites Coordinates and ERb Binding Sites Coordinates. Sheet 4:
Additional Table S4 Primary ERa target genes, showing ERa binding sites
within 10 kb of the TU in ERb- cells. Overview of the 228 putative ERa
primary gene targets containing the following additional information:
Symbol, Entrez ID, Gene Name, TU Coordinates.
Additional File 4: GO analysis of primary ERb target genes.
Containing the following information: Biological process, Gene Ontology
term, Name, Count in total GO population, Count in selected genes, %
genes and p-value.
Additional File 5: GO analysis of primary ERa target genes.
Containing the following information: Biological process, Gene Ontology
term, Name, Count in total GO population, Count in selected genes, %
genes and p-value.
Additional File 6: ERb binding sites in proximity of miRNA loci.
Containing the following information: miRNA name, ID of ER-b binding
site upstream, Distance from the closest ERb binding site upstream, ID of
ER-b binding site downstream and Distance from the closest ERb
binding site downstream.
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